Vistagen Therapeutics, Inc.
For the period ended Sep 30, 2025. Filed Nov 13, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 13, 2025
VTGN$0.18-0.7%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
(in thousands)
| Six Months EndedSeptember 30, | ||
|---|---|---|
| 2025 | 2024 | |
| Cash flows from operating activities: | ||
| Net loss | $(34,512) | $(23,694) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Depreciation and amortization | 93 | 71 |
| Stock-based compensation | 2,012 | 2,272 |
| Amortization of operating lease right-of-use asset | 261 | 237 |
| Non-cash interest expense | 2 | — |
| Accretion on marketable securities | (270) | (159) |
| Changes in operating assets and liabilities: | ||
| Prepaid expenses and other current assets | (165) | (864) |
| Other assets | (37) | 190 |
| Operating lease liability | (302) | (326) |
| Deferred revenue, net of deferred contract acquisition costs | (464) | (230) |
| Accounts payable and accrued expenses | 777 | 748 |
| Net cash used in operating activities | (32,605) | (21,755) |
| Cash flows from investing activities: | ||
| Purchases of laboratory and other equipment | (125) | (103) |
| Sales and maturities of marketable securities | 10,000 | 5,498 |
| Purchases of marketable securities | (10,757) | (18,648) |
| Net cash used in investing activities | (882) | (13,253) |
| Cash flows from financing activities: | ||
| Net proceeds from sale of common stock under Open Market Sale Agreement, net of offering costs | 28,325 | — |
| Net proceeds from sale of common stock under 2019 Employee Stock Purchase Plan | 161 | 88 |
| Issuance of note payable for insurance policy | 1,020 | — |
| Repayment of notes payable | (364) | — |
| Net cash provided by financing activities | 29,142 | 88 |
| Net change in cash and cash equivalents | (4,345) | (34,920) |
| Cash and cash equivalents at beginning of period | 67,131 | 119,166 |
| Cash and cash equivalents at end of period | $62,786 | $84,246 |
| Supplemental disclosure of noncash activities: | ||
| Non-cash investing and financing activities: | ||
| Cash paid for interest | $19 | $— |
| Purchases of equipment included in accounts payable and accrued liabilities | $8 | $— |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.